Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Keating

Showing results (171-180 of 436) with videos related to

Pageof 44
Sort By:
Blood Reviews|September 1, 1994
The role of fludarabine in hematological malignanciesS J Wright, L E Robertson, S O'Brien, et al.
Leukemia|May 21, 2016
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytesF Cervantes-Gomez, V Kumar Patel, P Bose, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1995
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemiaV Gandhi, E Estey, M Du, et al.
Leukemia|November 1, 1992
New drugs in the treatment of chronic lymphocytic leukemiaM J Keating, S O'Brien, L Robertson, et al.
Cancer Research|November 1, 1990
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemiaR Grunewald, H Kantarjian, M J Keating, et al.
British Journal of Haematology|October 29, 2000
Allogeneic haematopoietic transplantation for Richter's syndromeJ Rodriguez, M J Keating, S O'Brien, et al.
Leukemia|March 1, 1996
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcomeL E Robertson, W Plunkett, K McConnell, et al.
Leukemia & Lymphoma|January 1, 1993
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-CE H Estey, W Plunkett, H Kantarjian, et al.
Seminars in Oncology|June 1, 1987
Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemiaE Estey, M J Keating, W Plunkett, et al.
Cancer|January 15, 1981
Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapyC H Granatek, K Ezaki, E M Hersh, et al.
Pageof 44

Showing results (171-180 of 436) with videos related to

Sort By:
Pageof 44
Blood Reviews|September 1, 1994
The role of fludarabine in hematological malignanciesS J Wright, L E Robertson, S O'Brien, et al.
Leukemia|May 21, 2016
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytesF Cervantes-Gomez, V Kumar Patel, P Bose, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1995
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemiaV Gandhi, E Estey, M Du, et al.
Leukemia|November 1, 1992
New drugs in the treatment of chronic lymphocytic leukemiaM J Keating, S O'Brien, L Robertson, et al.
Cancer Research|November 1, 1990
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemiaR Grunewald, H Kantarjian, M J Keating, et al.
British Journal of Haematology|October 29, 2000
Allogeneic haematopoietic transplantation for Richter's syndromeJ Rodriguez, M J Keating, S O'Brien, et al.
Leukemia|March 1, 1996
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcomeL E Robertson, W Plunkett, K McConnell, et al.
Leukemia & Lymphoma|January 1, 1993
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-CE H Estey, W Plunkett, H Kantarjian, et al.
Seminars in Oncology|June 1, 1987
Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemiaE Estey, M J Keating, W Plunkett, et al.
Cancer|January 15, 1981
Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapyC H Granatek, K Ezaki, E M Hersh, et al.
Pageof 44